AB-205

AB-205 (E-CEL cells) is an allogeneic engineered endothelial cell therapy (genetically engineered human umbilical vein endothelial cells) from Angiocrine Bioscience, with California Institute for Regenerative Medicine as partner. Infused engineered blood-vessel lining cells meant to prevent or reduce the severe organ complications of high-dose chemotherapy before an autologous stem cell transplant. Supportive care for people with lymphoma, not a treatment of the cancer itself. Its furthest stage is phase 3, for hodgkin lymphoma and non-Hodgkin lymphoma (patients undergoing high-dose therapy and autologous transplant). ClinicalTrials.gov registers it in 2 studies linked below. Phase 3 E-CELERATE NCT05181540 TERMINATED: registry reason 'Interim analysis showed lack of efficacy'. No company statement on the programme found. Whether it works in people has not been established unless a trial below reports it.